Br J Cancer: Effect of ER expression status on the prognosmation of BRCA2 mutant breast cancer.

Previous studies have shown that carriers of BRCA2 mutations have a higher lifetime risk of breast cancer.
, however, it is not clear how the BRCA2 mutation affects patient survival or response to treatment.
BRCA1 mutation carriers are generally present as ER-negative breast cancer, in contrast, BRCA2 mutation carriers are generally ER-positive breast cancer.
pre-queue study published in 2016 by the University of Iceland showed that ER-positive patients with BRCA2 mutations showed poor prognostics and lower survival rates compared to ER-positive patients who did not carry the mutation.
the study collected clinical information on 608 patients with insanity breast cancer with pathogenic BRCA2 mutations from four Nordic countries (Denmark, Iceland, Norway and Sweden).
researchers obtained treatment and prognosmation information through health records and analysis of archived tissue specimens, and used Cox regression models to assess the risk ratio (HR) of breast cancer-specific survival rates.
to explore the relationship between prognossis factors, including ER expression, malignancy and various treatments, and breast cancer death.
incidence of breast cancer at different stages showed that about 77% of cancer patients were ER-positive, with the highest proportion (83%) under 40 years of age.
lymph nodes in ER-positive breast cancer was higher than in ER-negative breast cancer (59% to 34%).
survival analysis of 584 patients showed that ER-positive was a protective factor in the first 5 years of diagnosis (risk ratio of HR s 0.49), followed by adverse effects (HR s 1.91).
ER-positive reactions are limited to patients who have not received endocrine therapy (HR s 2.36) and complete ovaries (HR s 1.99).
, the results suggest that the adverse effects of ER-positive breast cancer in breast cancer patients with BRCA2 mutations may be caused by hormones secreted by the ovaries.
.